Table 2.
Association between SVR and the Risk of Developing Incident HE
| Number of patients (%) | Mean Follow-up(Years) | Number who developed HE (%) | HE incidence per 100 patient-years | Crude hazard ratio (95% CI) | Adjusted* hazard ratio (95%CI) | ||
|---|---|---|---|---|---|---|---|
| IFN-ONLY regimens | No SVR | 34,006(66.7) | 8.6 | 3,613(10.6) | 1.24 | 1 | 1 |
| SVR | 16,973(33.3) | 10.6 | 508(3.0) | 0.28 | 0.23(0.21–0.26) | 0.26(0.23–0.30) | |
| DAA+IFN regimens | No SVR | 3,198(42.4) | 3.3 | 132(4.1) | 1.26 | 1 | 1 |
| SVR | 4,345(57.6) | 5.2 | 74(1.7) | 0.33 | 0.27(0.20–0.37) | 0.31(0.22–0.43) | |
| DAA-only regimens | No SVR | 3,336(10.2) | 2.7 | 124(3.7) | 1.39 | 1 | 1 |
| SVR | 29,414(89.8) | 3.2 | 362(1.2) | 0.39 | 0.28(0.22–0.35) | 0.41(0.32–0.51) | |
| Cirrhosis | No SVR | 6,940(42.3) | 5.2 | 1,302(18.8) | 3.6 | 1 | 1 |
| SVR | 9,455(57.7) | 4.2 | 419(4.4) | 1.05 | 0.29(0.25–0.32) | 0.36(0.31–0.43) | |
| No Cirrhosis | No SVR | 33,600(44.9) | 8.2 | 2,567(7.6) | 0.93 | 1 | 1 |
| SVR | 41,277(55.1) | 6.2 | 525(1.3) | 0.2 | 0.23(0.20–0.25) | 0.25(0.22–0.28) | |
| Men | No SVR | 39,311(44.6) | 7.7 | 3,771(9.6) | 1.25 | 1 | 1 |
| SVR | 48,862(55.4) | 5.8 | 905(1.9) | 0.32 | 0.25(0.23–0.28) | 0.26(0.23–0.28) | |
| Women | No SVR | 1,209(39.5) | 8.2 | 91(7.5) | 0.91 | 1 | 1 |
| SVR | 1,855(60.5) | 6.4 | 39(2.1) | 0.33 | 0.34(0.22–0.51) | 0.35(0.20–0.62) | |
| Diabetes | No SVR | 8,800(42.9) | 6.9 | 936(10.6) | 1.55 | 1 | 1 |
| SVR | 11,731(57.1) | 4.7 | 288(2.5) | 0.52 | 0.33(0.29–0.39) | 0.36(0.30–0.44) | |
| No diabetes | No SVR | 31,740(44.9) | 7.9 | 2,933(9.2) | 1.17 | 1 | 1 |
| SVR | 39,001(55.1) | 6.2 | 656(1.7) | 0.27 | 0.23(0.21–0.26) | 0.26(0.23–0.30) | |
| Alcohol use disorder | No SVR | 14,647(42.0) | 7.0 | 1,393(9.5) | 1.36 | 1 | 1 |
| SVR | 20,226(58.0) | 5.3 | 406(2.0) | 0.38 | 0.27(0.24–0.31) | 0.31(0.27–0.37) | |
| No alcohol use disorder | No SVR | 25,893(45.9) | 8.1 | 2,476(9.6) | 1.19 | 1 | 1 |
| SVR | 30,506(54.1) | 6.2 | 538(1.8) | 0.28 | 0.24(0.22–0.27) | 0.27(0.23–0.31) | |
| Pre 2009 | No SVR | 27,308(68.5) | 9.4 | 3,216(11.8) | 1.25 | 1 | 1 |
| SVR | 12,583(31.5) | 11.8 | 407(3.2) | 0.27 | 0.22(0.20–0.25) | 0.25(0.21–0.29) | |
| 2009–2015 | No SVR | 13,232(25.8) | 4.1 | 653(4.9) | 1.19 | 1 | 1 |
| SVR | 38,149(74.2) | 3.9 | 537(1.4) | 0.36 | 0.29(0.26–0.33) | 0.30(0.26–0.34) | |
| MELD < 9 | No SVR | 28,555(43.0) | 7.6 | 2,348(8.2) | 1.08 | 1 | 1 |
| SVR | 37,820(57.0) | 5.7 | 552(1.5) | 0.25 | 0.24(0.22–0.27) | 0.27(0.24–0.30) | |
| MELD ≥9 | No SVR | 4,759(42.4) | 6.2 | 765(16.1) | 2.6 | 1 | 1 |
| SVR | 6,455(57.6) | 4.7 | 246(3.8) | 0.82 | 0.29(0.25–0.34) | 0.36(0.30–0.44) | |
| MELD ≥ 12 | No SVR | 1,881(39.8) | 5.5 | 303(16.1) | 2.92 | 1 | 1 |
| SVR | 2,849(60.2) | 4.2 | 126(4.4) | 1.06 | 0.34(0.27–0.42) | 0.39(0.29–0.52) | |
| MELD ≥ 15 | No SVR | 860(38.6) | 5.8 | 100(11.6) | 2.02 | 1 | 1 |
| SVR | 1,366(61.4) | 4.3 | 47(3.4) | 0.8 | 0.39(0.26–0.58) | 0.48(0.30–0.76) | |
| MELD ≥ 18 | No SVR | 591(42.1) | 6.0 | 66(11.2) | 1.87 | 1 | 1 |
| SVR | 812(57.9) | 4.4 | 19(2.3) | 0.53 | 0.29(0.17–0.49) | 0.30(0.14–0.61) | |
| MELD ≥ 21 | No SVR | 304(41.7) | 6.3 | 31(10.2) | 1.63 | 1 | 1 |
| SVR | 425(58.3) | 4.8 | 8(1.9) | 0.39 | 0.25(0.11–0.56) | 0.34(0.09–1.26) |
*
Adjusted for regimen type, cirrhosis, decompensated cirrhosis, age, sex, race/ethnicity, body mass index, HBV co-infection, type 2 diabetes mellitus, ascites, varices, hepatocellular carcinoma, alcohol use disorders, substance use disorder, platelet count, serum bilirubin, serum creatinine, serum albumin, INR and blood hemoglobin levels. The laboratory tests were categorized into quartiles and modeled as dummy categorical variables.